Breakpoint Therapeutics Announces Oral Presentation at the DDR Inhibitors Summit
- Jon Hollick will present preclinical data from Breakpoint’s polymerase theta (Pol θ / POLQ) inhibitor programme at the DDR Inhibitors Summit
Hamburg, Germany, 21 January 2026
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in an oral presentation at the DDR Inhibitors Summit, being held January 27-29, 2026 in Boston (MA), USA.
DNA polymerase theta is a DNA repair enzyme that is largely absent in normal cells but displays aberrant expression in multiple cancer types which often correlates with poor prognosis. Inhibition of Pol θ is a validated therapeutic modality in certain tumour-specific contexts.
Details of the presentation are as follows:
Title: Targeting Polθ’s Dual Domains to Guide Candidate Selection & Strategic Partnering
Date: Wednesday, 28 January, 2026
Time: 11:00 – 11:30 a.m. ET
In addition, Jon will participate in a panel discussion on the topic of “Uniting Founders and Funders to Align Scientific Vision with Investment Strategy” scheduled for Thursday, 29 January, 2026 at 8:30am.
– end –
About Breakpoint Therapeutics
Breakpoint Therapeutics is developing targeted cancer therapies that modulate DNA damage response (DDR) pathways. Through precise interference with DNA repair, our drug candidates are designed to kill cancer cells without harming healthy cells. We leverage new insights and the concept of synthetic lethality to increase the therapeutic window and achieve better outcomes for patients with therapy-resistant and hard-to-treat cancers.
For more about Breakpoint Therapeutics: www.breakpointtx.com
